Humans grow two sets of teeth in a lifetime. But tucked inside the jaw are tiny residual tooth buds that never develop because a protein called USAG-1 acts like a molecular off-switch for tooth growth. Block USAG-1, and the body might reactivate those dormant buds on its own.

Researchers at Kyoto University Hospital, led by Dr. Katsu Takahashi, have been working on this for years. They first found that mice engineered without the USAG-1 gene grew extra teeth. Later animal studies showed that a single antibody injection could grow fully functional teeth without serious safety issues.

The experimental drug is called TRG-035, a humanized anti-USAG-1 antibody developed by Toregem BioPharma. The first human trial began in October 2024 and enrolled 30 men aged 30 to 64, each missing at least one molar. The Phase I study was primarily a safety trial — a randomized, double-blind, placebo-controlled dose-escalation study. According to Toregem, Phase I confirmed the drug's safety, though detailed results haven't been made public yet. Researchers have noted that actual tooth regrowth in those adult participants was unlikely, since the volunteers were primarily establishing a safety profile before testing expands.

The next stage is where it gets more interesting. A Phase IIa trial is planned for 24 children aged 2 to 7 with severe congenital tooth agenesis — a condition where teeth never fully develop. Missing six or more teeth from birth affects roughly one in a thousand people, causing severe chewing difficulties and significant social stigma. The trial will be open-label and non-comparative, moving testing from healthy adults into the patients the drug is actually intended to treat.

There are still open questions. Experts have raised concerns about whether regrown teeth will align properly and connect correctly to nerves and blood vessels. If the trials succeed, Toregem aims for commercial availability around 2030, with early estimates placing costs at around $11,000 per tooth.

It's experimental. It's early. But the idea that human jaws might hold a dormant third set of teeth waiting for a chemical wake-up call is the kind of thing that sounds like science fiction until someone actually tries it.

9 hours ago: PUMA drops athlete’s line from online shop after HYROX defecation fiasco

2 hours ago: Joanna Wietrzyk issues apology statement

Event Summary:

For those who don't know, Joanna Wietrzyk was in an indoor HYROX competition this past weekend in Beijing. She had violent diarrhea (warning fecal images) during the event.

Other competitors had to do 'burpees' on her sprayed fecal matter, and had fecal matter on their hands and elbows. They also had to sit and share the same rowing machines as her, sitting in her fecal matter.

At the end of the race, she proudly proclaimed:

"Go hard or go home … a win is a win. In all seriousness, thank you for all the support. I’ll be back soon x.".

The HYROX company issued this statement, clearly endorsing this sort of activity. Calling it Admirable and an amazing display of how far Elite Athletes can push the human body.

She is sorry that she is losing sponsors, that is clear.

And corporations wonder why nobody wants to stick around and be a loyal employee

• Source

In 2008, two brothers unknowingly created one of the most iconic internet dance clips of the electro era. Their synchronized Tecktonik routine quickly spread across YouTube and became a defining moment of early internet dance culture.

Wealth is getting centralized in disproportionate scale

Edit : To put into perspective, an average American family makes 87,000$ in one year, which is a fraction of 0.000000085577 in 1.022T $

Some guy points a flashlight into the web of a very lucky spider!

Prolly still running.

A man working from his parents' house in West London made tens of millions of dollars trading futures from a bedroom filled with stuffed toys. His name is Navinder Singh Sarao, and he's on the autism spectrum.

There was no Wall Street trading floor. Sarao worked out of the family home in Hounslow, using a customized trading program on an ordinary desktop computer, and by most accounts he lived a pretty quiet life.

Then came May 6, 2010. In a matter of minutes, US stock markets plunged, and nearly $1 trillion in value briefly vanished before prices bounced back. It became known as the Flash Crash.

Years later, US authorities said Sarao's spoofing helped make it worse. Prosecutors said he placed large sell orders he never intended to fill, then canceled them, which pushed prices down so he could profit from the swings. They said his strategy was running on the day of the crash, and that he made more than $40 million from this kind of trading over several years.

Sarao fought extradition from the UK for years. He eventually pleaded guilty to wire fraud and spoofing in the US. His lawyers pointed to his autism, and the judge sentenced him to time served followed by home confinement rather than more prison time, citing his cooperation with prosecutors.